Formulation Development and In Vitro Evaluation of Propranolol Hydrochloride Extended Release Matrix Tablets
DOI:
https://doi.org/10.7324/ELSR.2017.313847Keywords:
differential scanning calorimetry, extended release tablets, fourier transforms infrared spectrophotometry, Propranolol, in vitro drug releaseAbstract
The purpose of this investigation is to develop extended release matrix tablets of propranolol hydrochloride (PPH), which were designed to improve the patient compliance and prolong the drug release after oral administration. Different viscosity grades of hydroxypropyl methylcellulose (HPMC) polymers such as HPMC K4 M, HPMC K15 M and HPMC K100 M were used. The prepared formulations were characterized and all formulations exhibited satisfactory physical parameters such as thickness (mm), weight variation (mg), friability (%) and hardness (kg/cm2). After evaluation of physical properties, the in vitro release study was performed in 0.1 N Hydrochloric Acid (HCl), pH 1.2 for 2 hours followed by release in phosphate buffer pH 6.8 up to 12 hours. The effects of polymer concentration and polymer blend concentration were studied. Among all the formulations, formulation F3 which contains 40% HPMC K4M followed zero order kinetics via, swelling, diffusion and erosion. This study gives the preliminary idea about the development of extended release drug delivery systems of PPH. The in-vitro drug release exponent of the peppas equation suggests the drug release mechanism was super case II transport mechanism. Based on compatibility studies such as differential scanning calorimetry (DSC) and fourier transform infrared spectrophotometry (FT-IR), there was no interaction between the drug and excipients.
References
[1] L. Lachman, H. A. Lieberman and L. J. Kanig (2013). The theory and practice of industrial pharmacy, 4th ed. Edited by R.K. Khar, S.P. Vyas, F.J. Ahmad and G.K. Jain. CBS publishers and distributors.
[2] S. P. Vyas and R. K. Khar (2002). Targeted and controlled drug delivery. Novel carrier systems, JCBS Publications.
[3] P. Madhusudhan and S. Nazeer (2010). Extended release formulation. Int. J. Pharm. Tech., 2: 625-684.
[4] M. H. Ehab Ahmed (2002). Application and evaluation of extended release technology to loop diuretics (Ph.D, thesis). University of cincinnati. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1037205224
[5] D. M. Brahmankar and S. B. Jaiswal (2015). Biopharmaceutics and pharmacokinetics; a treatise. 3rd ed. New delhi, Vallabh prakashan.
[6] C. McKee, J. Soeda, E. Asilmaz, B. Sigalla, M. Morgan, N. Sinelli, and T. Roskams et al., (2013). Propranolol, a β-adrenoceptor antagonist, worsens liver injury in a model of non-alcoholic steatohepatitis. Biochem. Biophys. Res. Commun., 437: 597-602.
[7] K. F. Morris, E. J. Billiot, F. H. Billiot, C. B. Hoffman, A. A. Gladis, K. B. Lipkowitz and W. M. Southerland et al., (2015). Molecular dynamics simulation and NMR investigation of the association of the β-blockers atenolol and propranolol with a chiral molecular micelle. Chem. Phys., 457: 133-146
[8] K. D. Tripathi (2003). Eessentials of medical pharmacology. 5th ed. New delhi: Jaypee brothers.
[9] D. A. Williams and T. L. Temke (2002). Foye’s principles of medicinal chemistry. International student ed. Philadelphia: Lippincott williams and wilkins.
[10] L. M. Friedman, R. P. Byington, R. J. Capone, C. D. Furberg, S. Goldstein, E. Lichstein (1986). Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J. Am. Coll Cardiol., 7: 1-8.
[11] A. H. El-Sabbagh (2015). Oral propranolol: A useful treatment for infantile hemangioma. Journal of biomedical science and engineering, 8: 441-450. doi: 10.4236/jbise.2015.87041.
[12]. S. Vidydydhara, P. Rama Rao and J. A. Prasad (2004). Formulation and evaluation of propranolol hydrochloride oral controlled release matrix tablets. Indian J. Pharm. Sci., 66: 188-192.
[13] B. Amulyaratna, B. Priyadarshini, P. Sachin Kumar, S. Chandra Sekhar, L. Pravin Kumar and S. S. Kumar (2011). Formulation development and evaluation of propranolol hydrochloride sustained release tablet. Indian J. Pharmaceutics., 2: 9-12.
[14] K. Sanka., R. R. Pragada and P. R. Veeraredy (2015). pH dependent colon specific ketoprofen microspheres: screening of main effects of process and formulation variables using plackett-burman design. Lat. Am. J. Pharm., 34: 1195-1204.
[15] S. K. Vemula and P. R. Veerareddy (2011). Fast disintegrating tablets of flurbiprofen: formulation and characterization. Lat. Am. J. Pharm., 30:1135-1141.
[16] K. Sanka., R. R. Pragada and P. R. Veeraredy (2015). A pH-triggered delayed-release chronotherapeutic drug delivery system of aceclofenac for effective management of early morning symptoms of rheumatoid arthritis. J. Microencapsul., 32: 794-803.
[17] R. K. Jadi, R. Bomma and V. Sellappan (2016). Development of a new single unit dosage form of propranolol HCl extended release non-effervescent floating matrix tablets: In vitro and in vivo evaluation, J. App. Pharm. Sci., 6: 112-118.
[18] J. Siepmann and N. A. Peppas (2001). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Deliv. Rev., 48: 139-157.
[19] A. Martin (2001). Micromeritics. In: Martin A, Physical pharmacy. Baltimore, MD: Lippincott williams and wilkins.
[20] Indian pharmacopoeia (2014). Ministry of Health and Family welfare, Govt. of India. Indian pharmacopoeia company, Ghaziabad.
[21] Cheng Chinhwa, Wu PaoChu, Lee HsinYa and Hsu KuangYang (2014). Development and validation of an in vitro in vivo correlation (IVIVC) model for propranolol hydrochloride extended release matrix formulations. J. Food Drug Anal., 22: 257-263.
[22] H. A. Alhmoud, E. I. EI-Hallous, N. E. Ibrahim, A. O. Attia and E. S. Dessoky (2014). Formulation of propranolol hydrochloride controlled release tablets: Effect of surfactant charge and mechanism of drug release. Afr. J. Pharm. Pharmacol., 8: 1110-1117.
[23] D. Jadhav, R. Kharat, S. Jadhav and M. Patil (2015). Design and evaluation of sustained release matrix tablets of propranolol hydrochloride. Indo Am. J. Pharmaceutical Res., 5: 1109-1117.
[24] T. Pongjanyakul and S. Rojtanatanya (2012). Use of propranolol magnesium aluminium silicate intercalated complexes as drug reservoirs in polymeric matrix tablets. Indian J. Pharm. Sci., 74: 292-301.
[25] J. C. O. Villanova and V. O. Consiglieri (2011). Development and in vitro evaluation of propranolol hydrochloride controlled release tablets using HPMC as matrix former. Lat. Am. J. Pharm., 30: 729-736.
[26] M. Khandai, S. Chakraborty, A. Sharma, D. Panda, N. Khanam and S. K. Panda (2010). Development of propranolol hydrochloride matrix tablets: An investigation on effects of combination of hydrophilic and hydrophobic matrix formers using multiple comparison analysis. Int. J. Pharm. Sci. Rev. Res., 1: 1-7.
[27] M. Rosa, H. Zia and T. Rhodes (1994). Dosing and testing in-vitro of a bioadhesive and floating drug delivery system for oral application. Int. J. Pharm., 105: 65-70.
[28] S. Dash, P. N. Murthy, L. Nath and P. Chowdhury (2010). Kinetic modeling on drug release from controlled drug delivery systems, Acta Pol. Pharm., 67: 217-223.
[29] T. Higuchi (1963). Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices, J. Pharm. Sci., 52: 1145-1149.
[30] R.W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and N.A. Peppas (1983). Mechanisms of solute release from porous hydrophilic polymers, Int. J. Pharm., 15: 25-35.
[31]. P. Costa and J. M. S. Lobo (2001). Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci., 13:123-133.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 Author (s)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright © The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are properly credited, and the work is not modified or adapted.
